Coloplast A/S

CPSE:COLO B Stock Report

Market Cap: DKK 181.9b

Coloplast Past Earnings Performance

Past criteria checks 3/6

Coloplast has been growing earnings at an average annual rate of 4.9%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 8.9% per year. Coloplast's return on equity is 28.2%, and it has net margins of 18.7%.

Key information

4.9%

Earnings growth rate

4.0%

EPS growth rate

Medical Equipment Industry Growth-1.7%
Revenue growth rate8.9%
Return on equity28.2%
Net Margin18.7%
Next Earnings Update04 Feb 2025

Recent past performance updates

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21
Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Recent updates

An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued

Jan 09
An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Dec 04
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?

Nov 29
Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08
Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18
Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23
Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22
Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17
Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29
These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21
Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10
Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09
Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Apr 26
A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Apr 08
There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

Mar 21
Is Coloplast (CPH:COLO B) A Risky Investment?

Revenue & Expenses Breakdown

How Coloplast makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:COLO B Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2427,0305,05210,069913
30 Jun 2426,3034,9679,675925
31 Mar 2425,5264,9659,252901
31 Dec 2325,0014,8688,934889
30 Sep 2324,5004,7838,632872
30 Jun 2324,3334,7848,581858
31 Mar 2324,0744,8018,550864
31 Dec 2223,5154,6268,272877
30 Sep 2222,5794,7067,800866
30 Jun 2221,6204,7817,336856
31 Mar 2220,6064,7466,828819
31 Dec 2119,8574,8966,446774
30 Sep 2119,4264,8256,249755
30 Jun 2118,9164,5616,098723
31 Mar 2118,5004,3045,938720
31 Dec 2018,5704,2415,993725
30 Sep 2018,5444,1976,086708
30 Jun 2018,5723,9496,113698
31 Mar 2018,7524,0206,199691
31 Dec 1918,3303,9746,118680
30 Sep 1917,9393,8735,970692
30 Jun 1917,5554,1195,753686
31 Mar 1917,1813,9995,626671
31 Dec 1816,8153,8965,488663
30 Sep 1816,4493,8455,375640
30 Jun 1816,1953,8165,315619
31 Mar 1815,8823,7785,211605
31 Dec 1715,7283,7915,104594
30 Sep 1715,5283,7974,994574
30 Jun 1715,2873,2114,880565
31 Mar 1715,0613,2794,785551
31 Dec 1614,7803,2644,731521
30 Sep 1614,6813,1434,693509
30 Jun 1614,5631,2974,690494
31 Mar 1614,4171,0284,627477
31 Dec 1514,2649274,583458
30 Sep 1513,9098994,488442
30 Jun 1513,5023,1624,343437
31 Mar 1513,0963,2414,220418
31 Dec 1412,6662,4074,088406
30 Sep 1412,4282,3904,002390
30 Jun 1412,1842,2983,959375
31 Mar 1412,0082,2203,944370

Quality Earnings: COLO B has high quality earnings.

Growing Profit Margin: COLO B's current net profit margins (18.7%) are lower than last year (19.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: COLO B's earnings have grown by 4.9% per year over the past 5 years.

Accelerating Growth: COLO B's earnings growth over the past year (5.6%) exceeds its 5-year average (4.9% per year).

Earnings vs Industry: COLO B earnings growth over the past year (5.6%) did not outperform the Medical Equipment industry 11.4%.

Return on Equity

High ROE: Whilst COLO B's Return on Equity (28.16%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 15:06
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Robert BateBarclays
Hassan Al-WakeelBarclays